Has Raja Mehdi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $31,829 in general payments to Raja Mehdi, MD across 337 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Raja Mehdi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Raja Mehdi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Raja Mehdi, MD

Hematology & Oncology · Las Vegas, NVNPI 1366441743

Payments from drug & device makers

$31,829in general payments, 2019–2025

Across 337 payments — averaging $94.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Janssen Research & Development, LLC$18K
Rigel Pharmaceuticals, Inc.$3K
Daiichi Sankyo Inc.$2K
Johnson & Johnson$1K
AstraZeneca$742
Regeneron Healthcare Solutions, Inc.$515
plus $6K from 48 others

$640in research payments, 2019–2025

Across 1 payment — averaging $639.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$640

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Janssen Research & Development, LLC	26	$18,340
Rigel Pharmaceuticals, Inc.	5	$3,027
Daiichi Sankyo Inc.	83	$2,204
Johnson & Johnson	14	$1,216
AstraZeneca(2 entities)	34	$742
Regeneron Healthcare Solutions, Inc.	10	$515
Abbott	4	$503
Boston Scientific	4	$489
Pfizer	19	$382
Merck	15	$372
Sobi, Inc	9	$361
Fennec Pharmaceuticals, Inc.	3	$354
Foundation Medicine, Inc.	4	$289
Astellas Pharma US Inc	8	$268
Bristol Myers Squibb	8	$203
Karyopharm Therapeutics Inc.	3	$172
Caris MPI, Inc.	3	$172
Tactile Systems Technology Inc	4	$161
Sanofi	3	$150
EMD Serono, Inc.	5	$130
Tempus AI, Inc	5	$126
Novartis	5	$123
GSK	5	$112
E.r. Squibb & Sons, L.L.C.	4	$102
Lilly USA, LLC	6	$101
Intuitive Surgical	1	$100
Bayer	4	$96
Gilead	4	$85
Eisai Inc.	4	$80
Dendreon Pharmaceuticals LLC	2	$67
Array Biopharma Inc	3	$65
Tersera Therapeutics LLC	2	$62
Ipsen Biopharmaceuticals, Inc	2	$59
AbbVie	2	$55
Taiho Oncology, Inc.	2	$52
Genentech USA, Inc.	2	$50
Springworks Therapeutics, Inc.	2	$42
Exelixis Inc.	1	$37
Agios Pharmaceuticals, Inc.	1	$36
Spectrum Pharmaceuticals Inc.	2	$36
Beone Medicines USA, Inc.	1	$26
Sun Pharmaceutical Industries Inc.	1	$26
Incyte Corporation	1	$25
Genmab U.S., Inc.	1	$25
Coherus Oncology, Inc.	1	$25
Sumitomo Pharma America, Inc.	1	$24
Medtronic	1	$21
Boehringer Ingelheim	1	$21
Accord Healthcare, Inc.	1	$20
Legend Biotech USA Inc.	1	$19
Stemline Therapeutics Inc.	1	$19
Immunocore Limited	1	$16
Amgen	1	$15
ADC Therapeutics America, Inc.	1	$14

How this compares

$31,829 in reported general payments places this provider in the 45th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024

$4,232,775

Medicare patients

549

Services billed

181,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Las Vegas

Edwin KingsleyLas Vegas$9.2M
Nicholas VogelzangLas Vegas$8.3M
Oscar GoodmanLas Vegas$6M
Khawaja JahangirLas Vegas$2.5M
Carolyn MulroneyLas Vegas$1.5M
Wolfram SamlowskiLas Vegas$1.1M
Anuradha ThummalaLas Vegas$736K
Grzegorz ObaraLas Vegas$668K
Aaron GoodmanLas Vegas$480K
Vikas GuptaLas Vegas$300K

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →